Firefly Neuroscience Q2 FY26 net loss widens 8.24% to $US 1.98 million; revenue rises 72% to $US 514,000

• Firefly Neuroscience posted a Q2 net loss of $1.98 million, widening from the prior-year quarter’s $1.83 million loss.
• Revenue rose 72% year over year to $514,000, reflecting contributions from the Evoke Neuroscience acquisition.
• Operating loss widened to $1.97 million, while research and development expense increased 56% to $525,000 on higher product-development spending.
• Cash totaled $9.23 million at June 30, 2026, up from $2.75 million at year-end 2025 after $10.25 million in gross private-placement proceeds.
• The Evoke EEG System was in use across more than 85 U.S. clinical sites as of June 30, 2026; no shares were sold under its $7.43 million ATM program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Firefly Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026822), on August 11, 2026, and is solely responsible for the information contained therein.